Defne Bayik remembers the moment her team realized they’d uncovered something entirely new: in female mice with glioblastoma, a brain chemical best known for calming neurons was quietly shielding tumors from immune attack—while doing nothing of the sort in males. At the Sylvester Comprehensive Cancer Center in Miami, Bayik and her colleague Asmita Pathak had been probing the hidden differences in how glioblastoma, the most aggressive brain cancer, interacts with the immune system in males and females. What they found wasn’t just a clue—it was a female-specific biological pathway that could reshape how we treat cancer in women.
Glioblastoma strikes more men than women and tends to be more lethal in them, but survival in women remains poor, and standard therapies often fail. The team focused on myeloid-derived suppressor cells (MDSCs), immune cells that tumors exploit to shut down protective T cell responses. Earlier work had shown that males rely more on monocytic MDSCs, while females use granulocytic MDSCs (gMDSCs)—a subtle but critical distinction. In female models, these gMDSCs expressed receptors for GABA, the brain’s primary inhibitory neurotransmitter. Even more striking: GABA wasn’t just present—it was enhancing the immune-suppressing power of gMDSCs, effectively cloaking the tumor.
In experiments using female mice, the team observed significantly higher expression of GABA receptors Gabbr1, Gabbr2, and Gabra2 in gMDSCs compared to males—up to twofold differences, with p-values confirming statistical significance. This female-specific signaling pathway was absent in males, suggesting a fundamental sex-based divergence in tumor immunity. When the researchers blocked GABA signaling, the protective shield weakened, T cells regained activity, and tumor growth slowed. Among 20 drug candidates identified through network medicine analysis, three stood out for targeting this pathway: vigabatrin, progabide, and brotizolam—already approved for other conditions, which could accelerate their path to clinical testing.
The implications are profound. For decades, cancer research has largely treated male biology as the default. This study proves that in glioblastoma, the rules differ for women—and so must the treatments. By targeting a neurotransmitter pathway in immune cells, not neurons, these findings open a new frontier in immuno-oncology. While still in preclinical stages, the work offers a roadmap for sex-specific therapies that could improve survival for women battling this devastating disease.
As Bayik puts it: 'We’re not just fighting cancer—we’re finally seeing it clearly, in all its complexity.'